M
Mallory J E Loflin
Researcher at University of California, San Diego
Publications - 24
Citations - 956
Mallory J E Loflin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cannabis & Placebo. The author has an hindex of 9, co-authored 22 publications receiving 632 citations. Previous affiliations of Mallory J E Loflin include University at Albany, SUNY & VA Palo Alto Healthcare System.
Papers
More filters
Journal ArticleDOI
Labeling Accuracy of Cannabidiol Extracts Sold Online
Marcel O. Bonn-Miller,Mallory J E Loflin,Brian F. Thomas,Jahan P. Marcu,Travis Hyke,Ryan Vandrey +5 more
TL;DR: To maximize sampling and ensure representativeness of available products, this work examined the label accuracy of CBD products sold online, including identification of present but unlabeled cannabinoids.
Journal ArticleDOI
A new method of cannabis ingestion: the dangers of dabs?
TL;DR: It was revealed that using "dabs" created no more problems or accidents than using flower cannabis, and participants did report that "dabbing" led to higher tolerance and withdrawal (as defined by the participants), suggesting that the practice might be more likely to lead to symptoms of addiction or dependence.
Journal ArticleDOI
The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.
Mallory J E Loflin,Brian D. Kiluk,Marilyn A. Huestis,Will M. Aklin,Alan J. Budney,Kathleen M. Carroll,Deepak Cyril D'Souza,Robert H. Dworkin,Kevin M. Gray,Deborah S. Hasin,Dustin C. Lee,Bernard Le Foll,Frances R. Levin,Joshua A. Lile,Barbara J. Mason,Aimee L. McRae-Clark,Ivan D. Montoya,Erica N. Peters,Tatiana Ramey,Dennis C. Turk,Ryan Vandrey,Roger D. Weiss,Eric C. Strain +22 more
TL;DR: S sustained abstinence from cannabis should not be considered the primary outcome for all CUD clinical trials as it has multiple limitations and development of a core toolkit of assessments is needed to both allow flexibility for study design, while facilitating interpretation of outcomes across trials.
Journal ArticleDOI
Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.
TL;DR: This commentary discusses the unique challenges and merits of botanical vs single molecule cannabinoid drug development strategies, highlights how both can be impacted by legalization of cannabis via legislative processes, and also addresses regulatory and public health considerations that are important to consider as cannabinoid medicine advances as a discipline.
Journal ArticleDOI
Medicinal versus recreational cannabis use: Patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD.
TL;DR: Compared to those who use cannabis recreationally, veterans who report that they use cannabis medicinally use more cannabis and endorse significantly more symptoms of arousal following a prompt about combat trauma experiences.